- Lantern Pharma has publicly launched predictBBB.ai (TM), its AI-driven module for predicting small-molecule blood-brain barrier permeability.
- The tool achieves 94% prediction accuracy, with 95% sensitivity and 89% specificity, based on real-time ensemble machine learning.
- Powered by Lantern’s vast molecular features data lake and ensemble algorithms, the platform sets a new computational benchmark for CNS drug discovery.
- Lantern hosts additional predictive and analytical modules in development, leveraging its large-scale data infrastructure and algorithmic approach.
- The tool is publicly accessible through a freemium model, aiming to drive adoption, strategic partnerships, and accelerate CNS therapeutic development.
- Lantern Pharma subsidiary Starlight Therapeutics secures FDA IND clearance for its Phase Ib/IIa trial combining STAR-001 (“LP-184”) and spironolactone in recurrent glioblastoma multiforme.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has introduced predictBBB.ai(TM), a publicly available AI module designed to predict blood-brain barrier (“BBB”) permeability for small-molecule drugs with unprecedented speed and accuracy (https://ibn.fm/9RZYo).
Crossing the BBB remains one of the pharmaceutical industry’s most persistent challenges. Traditionally, only 2-6% of small molecules manage to penetrate this critical barrier. Lantern Pharma aims to transform this bottleneck by providing researchers with real-time predictions powered by billions of molecular data points drawn from its proprietary molecular features data lake.
The module’s performance metrics speak for themselves: 94% accuracy, 95% sensitivity, and 89% specificity, all achieved through an ensemble of machine learning models including logistic regression, random forests, SVMs, and deep neural networks.
By claiming five of the top eleven slots on the Therapeutic Data Commons leaderboard, Lantern Pharma demonstrates clear technological superiority over academic and commercial competitors.
Lantern is offering predictBBB.ai(TM) via a freemium model, granting open access to foundational BBB prediction tools while positioning more advanced functionality for partnership-driven deployment. This strategy aims to foster early adoption among pharma and academia, leading to longer-term collaborations.
“We’re witnessing unprecedented demand for AI-driven solutions that deliver measurable impact on pharmaceutical development success rates,” said Panna Sharma, Chief Executive Officer of Lantern Pharma. “Our BBB prediction module establishes the foundation for deeper partnerships that leverage our comprehensive platform capabilities to accelerate therapeutic development across diverse disease areas while maintaining the highest standards of scientific rigor and predictive accuracy.”
The module’s architecture is built on real-time processing of SMILES molecular input via ensemble algorithms, underpinned by advanced feature engineering and synthetic data augmentation. Lantern plans to expand its suite of AI modules to cover a wider range of drug development properties, leveraging the same robust data and architecture. Predicting BBB permeability early can significantly reduce costly failures in CNS drug development, where failure rates and costs remain critically high. Lantern’s tool could lower risk and timeline for brain cancer and neurological therapies
“This public release has the potential to be a paradigm shift in how pharmaceutical organizations and researchers approach CNS drug development,” Sharma added. “Our technology transforms what has historically been one of drug discovery’s critical bottlenecks into a competitive advantage. By democratizing access to industry-leading BBB prediction capabilities through our freemium approach, we’re enabling researchers worldwide to accelerate therapeutic development while building strategic partnerships that drive innovation.”
The release aligns with Lantern’s broader RADR(R) AI platform, which integrates this BBB module alongside other predictive tools for molecular and clinical performance, collectively enabling more efficient therapeutic development, especially in CNS and oncology domains.
Complementing this technological advance, Lantern Pharma’s subsidiary Starlight Therapeutics secured Food and Drug Administration IND (investigational new drug) clearance for its Phase Ib/IIa trial combining STAR-001 (“LP-184”) and spironolactone in recurrent glioblastoma multiforme (“GBM”); a study enabled by Lantern’s AI-driven RADR(R) platform (https://ibn.fm/PScS6). The company is currently undergoing a Phase Ia trial to determine dosing, safety, and the maximum tolerated dose across various solid tumors, including GBM.
Starlight is planning to initiate the Phase Ib/IIa trial between late 2025 and early 2026, with the goal of assessing the tolerability, preliminary efficacy, and safety of the combination therapy in individuals with recurrent GBM.
For more information, visit the company’s website at www.LanternPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com
MissionIR is powered by IBN